Mineralys Therapeutics, Inc. MLYS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $24.37M-35.7% | $24.4M-45.2% | $31.45M-41.7% | $38.28M-2.5% | $37.88M+23.2% | ||
| $20.98M+219% | $13.88M+92.8% | $9.68M+58.2% | $8.47M+43.6% | $6.57M+42.5% | ||
| $45.34M+2.0% | $38.28M-26.1% | $41.13M-31.6% | $46.75M+3.5% | $44.45M+25.7% | ||
| -$45.34M-2.0% | -$38.28M+26.1% | -$41.13M+31.6% | -$46.75M-3.5% | -$44.45M-25.7% | ||
| $6M+168% | $6.05M+115% | $4.2M+11.2% | $3.47M-16.3% | $2.24M-41.9% | ||
| $6M+168% | $6.05M+114% | $4.2M+11.6% | $3.47M-16.4% | $2.24M-42.0% | ||
| -$39.34M+6.8% | -$32.23M+34.1% | -$36.93M+34.5% | -$43.27M-5.5% | -$42.21M-34.0% | ||
| -$0.47+40.5% | -$0.35+64.3% | -$0.52+54.0% | -$0.66+20.5% | -$0.79-12.9% | ||
| -$45.33M-2.0% | -$38.27M+26.1% | -$41.12M+31.6% | -$46.73M-3.5% | -$44.43M-25.7% | ||
| -$45.34M-2.0% | -$38.28M+26.1% | -$41.13M+31.6% | -$46.75M-3.5% | -$44.45M-25.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Mineralys Therapeutics, Inc. profitable?
- Mineralys Therapeutics, Inc. is not currently profitable: it reported a net loss of $151.8M over the trailing twelve months.
- What is Mineralys Therapeutics, Inc.'s earnings per share?
- Mineralys Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.00.
- Where does Mineralys Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.